" class="no-js "lang="en-US"> Oscar Matzinger - Medtech Alert
Monday, September 15, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Oscar Matzinger

Oscar Matzinger

About Oscar Matzinger

Professor Matzinger is Medical Director Radiation Oncology for the Swiss Medical Network and Head of Radiation Oncology at the Clinique de Genolier and the Centre d’Oncologie des Eaux-Vives in Geneva. He is also Vice President of the Swiss Society for Radiation Oncology.

Related Story

Diseases

 RayCare In Clinical Use With CyberKnife at Swiss Medical Network in Switzerland | Pharmtech Focus

RayCare In Clinical Use With CyberKnife at Swiss Medical Network in Switzerland

May 9 2022

RaySearch Laboratories AB (publ) announces that La Clinique Générale-Beaulieu, a part of Swiss Medical Network […]